The stock of Charles River Laboratories International Inc. (CRL) has seen a 7.87% increase in the past week, with a 3.52% gain in the past month, and a -0.00% decrease in the past quarter. The volatility ratio for the week is 2.57%, and the volatility levels for the past 30 days are at 2.54% for CRL. The simple moving average for the last 20 days is 5.96% for CRL stock, with a simple moving average of -6.75% for the last 200 days.
Is It Worth Investing in Charles River Laboratories International Inc. (NYSE: CRL) Right Now?
The price-to-earnings ratio for Charles River Laboratories International Inc. (NYSE: CRL) is above average at 24.78x. The 36-month beta value for CRL is also noteworthy at 1.36. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 5 rating it as “overweight,” 8 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CRL is 51.04M, and at present, short sellers hold a 2.86% of that float. The average trading volume of CRL on September 20, 2024 was 661.07K shares.
CRL) stock’s latest price update
The stock of Charles River Laboratories International Inc. (NYSE: CRL) has increased by 1.71 when compared to last closing price of 206.10. Despite this, the company has experienced a 7.87% gain in its stock price over the last five trading sessions. businesswire.com reported 2024-09-19 that STOCKHOLM–(BUSINESS WIRE)–Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap™ technology to develop enhanced cancer therapies, today announced significant progress following a productive meeting with the U.S. Food and Drug Administration (FDA). The company plans to resubmit its New Drug Application (NDA) for Dasynoc in Q4 2024, incorporating feedback from the Complete Response Letter (CRL) issued by FDA in July 2024. If the FDA sets a.
Analysts’ Opinion of CRL
Many brokerage firms have already submitted their reports for CRL stocks, with Robert W. Baird repeating the rating for CRL by listing it as a “Neutral.” The predicted price for CRL in the upcoming period, according to Robert W. Baird is $191 based on the research report published on August 08, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see CRL reach a price target of $205, previously predicting the price at $270. The rating they have provided for CRL stocks is “Neutral” according to the report published on August 08th, 2024.
CRL Trading at -0.03% from the 50-Day Moving Average
After a stumble in the market that brought CRL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.77% of loss for the given period.
Volatility was left at 2.54%, however, over the last 30 days, the volatility rate increased by 2.57%, as shares surge +2.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.41% upper at present.
During the last 5 trading sessions, CRL rose by +7.87%, which changed the moving average for the period of 200-days by +3.94% in comparison to the 20-day moving average, which settled at $198.09. In addition, Charles River Laboratories International Inc. saw -11.33% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRL starting from LaPlume Joseph W, who sale 1,780 shares at the price of $199.36 back on Aug 08 ’24. After this action, LaPlume Joseph W now owns 22,521 shares of Charles River Laboratories International Inc., valued at $354,861 using the latest closing price.
Joseph LaPlume, the Officer of Charles River Laboratories International Inc., proposed sale 1,780 shares at $196.63 during a trade that took place back on Aug 08 ’24, which means that Joseph LaPlume is holding shares at $350,000 based on the most recent closing price.
Stock Fundamentals for CRL
Current profitability levels for the company are sitting at:
- 0.15 for the present operating margin
- 0.34 for the gross margin
The net margin for Charles River Laboratories International Inc. stands at 0.11. The total capital return value is set at 0.09. Equity return is now at value 12.54, with 5.56 for asset returns.
Based on Charles River Laboratories International Inc. (CRL), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at 0.31. The debt to equity ratio resting at 0.64. The interest coverage ratio of the stock is 4.42.
Currently, EBITDA for the company is 1.03 billion with net debt to EBITDA at 2.58. When we switch over and look at the enterprise to sales, we see a ratio of 3.31. The receivables turnover for the company is 5.35for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.58.
Conclusion
In summary, Charles River Laboratories International Inc. (CRL) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
